Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation

Ann-Katrin Mojica Munoz, Janina Jamasbi, Kerstin Uhland, Heidrun Degen, Goetz Muench, Martin Ungerer, Richard Brandl, Remco Megens, Christian Weber, Reinhard Lorenz, Wolfgang Siess*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1651-1659
Number of pages9
JournalThrombosis and Haemostasis
Volume117
Issue number8
DOIs
Publication statusPublished - Aug 2017

Keywords

  • Antiplatelet agents
  • Atherothrombosis
  • GP VI
  • GP IIb/IIIa
  • Ischaemic heart disease
  • MULTIPLE ELECTRODE AGGREGOMETRY
  • GLYCOPROTEIN-VI
  • ATHEROSCLEROTIC PLAQUES
  • RECEPTOR ANTAGONISTS
  • FLOWING BLOOD
  • WHOLE-BLOOD
  • COLLAGEN
  • AGGREGATION
  • FUTURE
  • INHIBITION

Cite this

Munoz, A-K. M., Jamasbi, J., Uhland, K., Degen, H., Muench, G., Ungerer, M., Brandl, R., Megens, R., Weber, C., Lorenz, R., & Siess, W. (2017). Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation. Thrombosis and Haemostasis, 117(8), 1651-1659. https://doi.org/10.1160/TH16-11-0856